dc.contributor.author | Prieto-Pérez, Rocío | |
dc.contributor.author | Almoguera, Berta | |
dc.contributor.author | Cabaleiro, Teresa | |
dc.contributor.author | Hakonarson, Hakon | |
dc.contributor.author | Abad Santos, Francisco | |
dc.contributor.other | UAM. Departamento de Farmacología | es_ES |
dc.date.accessioned | 2017-01-25T18:37:29Z | |
dc.date.available | 2017-01-25T18:37:29Z | |
dc.date.issued | 2016-02-06 | |
dc.identifier.citation | International Journal of Molecular Sciences 17.2 (2016): 225 | en_US |
dc.identifier.issn | 1661-6596 (print) | es_ES |
dc.identifier.issn | 1422-0067 (online) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/676585 | |
dc.description.abstract | Tumor necrosis factor (TNF) is a major proinflammatory cytokine involved in the immune
response in inflammatory bowel disease (IBD). Anti-TNF drugs such as infliximab and adalimumab
are used to treat IBD; however, approximately 30% of patients do not respond to treatment. Individual
genetic differences could contribute to lack of efficacy. Genetic studies have tried to uncover the
factors underlying differences in response, however, knowledge remains limited, and the results
obtained should be validated, so that pharmacogenetic information can be applied in clinical practice.
In this review, we gather current knowledge in the pharmacogenetics of anti-TNF drugs in patients
with IBD. We observed a connection between the major genes described as possible predictors of
response to anti-TNF drugs in IBD and the cytokines and molecules involved in the T helper (Th)
17 pathway | en_US |
dc.description.sponsorship | This study was supported by Fundación Teófilo Hernando. Rocío Prieto-Pérez has a grant
from Universidad Autónoma de Madrid (research personnel in training (FPI) program 2013). | en_US |
dc.format.extent | 8 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | MDPI | es_ES |
dc.relation.ispartof | International Journal of Molecular Sciences | en_US |
dc.subject.other | Inflammatory bowel disease | en_US |
dc.subject.other | Polymorphisms | en_US |
dc.subject.other | Pharmacogenomics | en_US |
dc.subject.other | Adalimumab | en_US |
dc.subject.other | Infliximab | en_US |
dc.title | Association between genetic polymorphisms and response to anti-TNFs in patients with inflammatory bowel disease | en |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.3390/ijms17020225 | es_ES |
dc.identifier.doi | 10.3390/ijms17020225 | es_ES |
dc.identifier.publicationfirstpage | 225-1 | es_ES |
dc.identifier.publicationissue | 2 | es_ES |
dc.identifier.publicationlastpage | 225-16 | es_ES |
dc.identifier.publicationvolume | 17 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Abad Santos, Francisco (259532) | |
dc.facultadUAM | Facultad de Medicina | |